Angiotensin-converting enzyme inhibitors and calcium antagonists after acute myocardial infarction.
This article examines trials of the use of two types of drugs in the treatment of myocardial infarction: angiotensin-converting enzyme (ACE) inhibitors and calcium antagonists. ACE inhibitors are an established treatment for hypertension and heart failure and have been shown to reduce mortality from heart failure and after myocardial infarction. Six large studies have been carried out. In 1 in which an ACE inhibitor was given 3-16 days after infarction in patients with an ejection fraction < 40%, mortality was reduced by 17%. In a second study of patients who had evidence of heart failure and were followed up for 15 months, treatment with ACE inhibitors was given 3-10 days after myocardial infarction and mortality was reduced by 27%. Two other studies of 11,000 and 50,000 unselected patients with myocardial infarction showed only marginal clinical benefit. Calcium antagonists were introduced to treat hypertension and angina pectoris. In trials with patients with heart failure, the results have not been encouraging, and in some patients these agents seem to be harmful. Recently, long-acting calcium antagonists have become available, and these may avoid the deleterious effects of short-acting drugs. Since calcium antagonists act on smooth muscle, they may increase myocardial blood flow to improve function after "stunning" or "hibernation." This idea was investigated with a long-acting dihydroyridine calcium, antagonist in a randomized double-blind, placebo-controlled study (Doppler Flow, Echocardiography, and Functional Improvement Assessment of Nisoldipine Therapy-I--DEFIANT I), and a further study is being carried out. At present the widespread use of calcium antagonists after infarction is not recommended.
Poole-Wilson
P A
PA
Department of Cardiac Medicine, National Heart and Lung Institute, London, United Kingdom.
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality
D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers